Article Text
Declarations of Interest
P156 Efficacy, safety and tolerability of once-daily tiotropium respimat® add-on therapy in children with moderate symptomatic asthma
Abstract
O Schmidt has received research grants from Boehringer Ingelheim;
E Hamelmann has received research grants and other fees from Boehringer Ingelheim and non-financial support from Boehringer Ingelheim;
C Vogelberg has participated in an advisory board for Boehringer Ingelheim;
I Laki has nothing to disclose;
G El Azzi is an employee of Boehringer Ingelheim;
M Engel is an employee of Boehringer Ingelheim;
P Moroni-Zentgraf is an employee of Boehringer Ingelheim;
H Finnigan is an employee of Boehringer Ingelheim;
M Vandewalker has received research grants and personal fees from Boehringer Ingelheim.